300558 贝达药业
交易中 12-10 14:10:33
资讯
新帖
简况
贝达药业最新公告：公司四款产品纳入《国家医保药品目录》
证券之星 · 12-07 16:20
贝达药业最新公告：公司四款产品纳入《国家医保药品目录》
贝达药业(300558.SZ)：目前未有贝福替尼和泰瑞西利的全球多中心临床计划
中金财经 · 12-02
贝达药业(300558.SZ)：目前未有贝福替尼和泰瑞西利的全球多中心临床计划
贝达药业：梦工场已支持超20家创新企业
证券之星 · 12-02
贝达药业：梦工场已支持超20家创新企业
贝达药业：辉瑞友瑞宁上市不会对晟斯生物产品构成重大竞争风险
证券之星 · 12-02
贝达药业：辉瑞友瑞宁上市不会对晟斯生物产品构成重大竞争风险
贝达药业：目前未有与华昊生物的项目合作
证券之星 · 12-02
贝达药业：目前未有与华昊生物的项目合作
贝达药业：通过“四驾马车”协同发力实现跨越式发展
证券之星 · 12-02
贝达药业：通过“四驾马车”协同发力实现跨越式发展
贝达药业：两地定价核心逻辑会相互影响
证券之星 · 12-02
贝达药业：两地定价核心逻辑会相互影响
贝达药业：H股募集资金将用于在研管线研发及潜在收购
证券之星 · 12-02
贝达药业：H股募集资金将用于在研管线研发及潜在收购
贝达药业：嵊州基地将承接上市药品生产需求
证券之星 · 12-02
贝达药业：嵊州基地将承接上市药品生产需求
贝达药业：恩沙替尼术后辅助治疗适应症上市许可申请已获受理
证券之星 · 12-02
贝达药业：恩沙替尼术后辅助治疗适应症上市许可申请已获受理
贝达药业(300558.SZ)：盐酸恩沙替尼胶囊上市许可申请获得欧洲药品管理局受理
智通财经 · 11-28
贝达药业(300558.SZ)：盐酸恩沙替尼胶囊上市许可申请获得欧洲药品管理局受理
贝达药业(300558.SZ)：盐酸恩沙替尼胶囊术后辅助治疗适应症药品注册申请获得受理
智通财经 · 11-26
贝达药业(300558.SZ)：盐酸恩沙替尼胶囊术后辅助治疗适应症药品注册申请获得受理
11月14日贝达药业现1笔折价19.77%的大宗交易 合计成交300.7万元
证券之星 · 11-14
11月14日贝达药业现1笔折价19.77%的大宗交易 合计成交300.7万元
贝达药业：截至2025年6月30日公司共有1,800余名员工
证券之星 · 11-11
贝达药业：截至2025年6月30日公司共有1,800余名员工
贝达药业：与瑞普晨创合作推进1型糖尿病细胞治疗
证券之星 · 11-11
贝达药业：与瑞普晨创合作推进1型糖尿病细胞治疗
贝达药业：四驾马车协同发展提升内在价值
证券之星 · 11-11
贝达药业：四驾马车协同发展提升内在价值
贝达药业：恩沙替尼术后辅助治疗达主要研究终点
证券之星 · 11-06
贝达药业：恩沙替尼术后辅助治疗达主要研究终点
贝达药业：BPI-572270是一款分子胶抑制剂，目前该项目正推进提交临床研究申请（IND）准备工作
每日经济新闻 · 11-06
贝达药业：BPI-572270是一款分子胶抑制剂，目前该项目正推进提交临床研究申请（IND）准备工作
贝达药业：MCLA-129、CFT8919项目正在临床研究中
证券之星 · 11-06
贝达药业：MCLA-129、CFT8919项目正在临床研究中
贝达药业：2025年1-9月实现营业收入27.17亿元
证券之星 · 11-06
贝达药业：2025年1-9月实现营业收入27.17亿元
公司概况
公司名称：
贝达药业股份有限公司
所属行业：
医药制造业
上市日期：
2016-11-07
主营业务：
贝达药业股份有限公司的主营业务是创新药物的生产与销售。公司的主要产品是凯美纳、贝美纳、贝安汀、赛美纳、伏美纳、康美纳、安瑞泽、奥福民。
发行价格：
17.57
{"stockData":{"symbol":"300558","market":"SZ","secType":"STK","nameCN":"贝达药业","latestPrice":48.56,"timestamp":1765347033000,"preClose":48.23,"halted":0,"volume":4172676,"delay":0,"changeRate":0.0068,"floatShares":419000000,"shares":421000000,"eps":0.7209,"marketStatus":"交易中","change":0.33,"latestTime":"12-10 14:10:33","open":48.11,"high":48.88,"low":47.54,"amount":202000000,"amplitude":0.0278,"askPrice":48.58,"askSize":6,"bidPrice":48.56,"bidSize":71,"shortable":0,"etf":0,"ttmEps":0.7209,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1765350000000},"marketStatusCode":2,"adr":0,"adjPreClose":48.23,"symbolType":"stock","openAndCloseTimeList":[[1765330200000,1765337400000],[1765342800000,1765350000000]],"highLimit":53.05,"lowLimit":43.41,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":420733843,"isCdr":false,"pbRate":3.47,"roa":"--","peRate":67.360244,"roe":"5.5%","epsLYR":0.96,"committee":-0.370192,"marketValue":20431000000,"turnoverRate":0.0099,"status":0,"floatMarketCap":20366000000},"requestUrl":"/m/hq/s/300558/wiki","defaultTab":"wiki","newsList":[{"id":"2589689879","title":"贝达药业最新公告：公司四款产品纳入《国家医保药品目录》","url":"https://stock-news.laohu8.com/highlight/detail?id=2589689879","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589689879?lang=zh_cn&edition=full","pubTime":"2025-12-07 16:20","pubTimestamp":1765095612,"startTime":"0","endTime":"0","summary":"贝达药业(300558.SZ)公告称，公司产品盐酸埃克替尼片（凯美纳）、盐酸恩沙替尼胶囊（贝美纳）、甲磺酸贝福替尼胶囊（赛美纳）以及伏罗尼布片（伏美纳）被纳入《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》。此次纳入将提高产品的可及性，对销售产生积极影响。但对公司当期经营业绩的影响目前无法准确估计。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120700003973.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91287","300558","BK0060","BK0239"],"gpt_icon":0},{"id":"2588908882","title":"贝达药业(300558.SZ)：目前未有贝福替尼和泰瑞西利的全球多中心临床计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2588908882","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588908882?lang=zh_cn&edition=full","pubTime":"2025-12-02 10:07","pubTimestamp":1764641223,"startTime":"0","endTime":"0","summary":"格隆汇12月2日丨贝达药业(300558.SZ)在投资者互动平台表示，公司目前未有贝福替尼和泰瑞西利的全球多中心临床计划，如有重大合作或交易公司会及时公开披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251202/31837584.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300558","BK0239","BK0060","91287"],"gpt_icon":0},{"id":"2588870222","title":"贝达药业：梦工场已支持超20家创新企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2588870222","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588870222?lang=zh_cn&edition=full","pubTime":"2025-12-02 09:03","pubTimestamp":1764637392,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业12月02日在投资者关系平台上答复投资者关心的问题。贝达梦工厂总面积多少？贝达梦工场作为创新生态圈两翼之一，目前正处于持续的开发中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200004591.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91287","300558","BK0060","BK0239"],"gpt_icon":0},{"id":"2588270224","title":"贝达药业：辉瑞友瑞宁上市不会对晟斯生物产品构成重大竞争风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2588270224","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588270224?lang=zh_cn&edition=full","pubTime":"2025-12-02 09:02","pubTimestamp":1764637329,"startTime":"0","endTime":"0","summary":"血友病治疗领域不同产品在作用机制、给药方式、适用人群等方面存在差异，市场竞争呈现多元化格局，存在未被满足的临床需求，辉瑞友瑞宁的上市不会对晟斯生物相关合作产品构成重大竞争风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200004562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","91287","BK0060","300558"],"gpt_icon":0},{"id":"2588702181","title":"贝达药业：目前未有与华昊生物的项目合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2588702181","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588702181?lang=zh_cn&edition=full","pubTime":"2025-12-02 08:57","pubTimestamp":1764637045,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)12月02日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，贵公司与华昊生物有没有项目合作？贝达药业回复：您好！公司目前未有与华昊生物的项目合作。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200004464.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91287","300558","BK0060","BK0239"],"gpt_icon":0},{"id":"2588702979","title":"贝达药业：通过“四驾马车”协同发力实现跨越式发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2588702979","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588702979?lang=zh_cn&edition=full","pubTime":"2025-12-02 08:57","pubTimestamp":1764637042,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业12月02日在投资者关系平台上答复投资者关心的问题。面对行业的迅猛发展，贝达对标高质量发展，迎难而上、主动求变，提出了未来五年的发展规划和重点领域，通过“四驾马车”协同发力，在核心创新力、人才资源、制度保障以及执行力方面均力争更大的突破，推动公司实现跨越式发展，全力创造公司价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200004462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91287","BK0239","BK0060","300558"],"gpt_icon":0},{"id":"2588702523","title":"贝达药业：两地定价核心逻辑会相互影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2588702523","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588702523?lang=zh_cn&edition=full","pubTime":"2025-12-02 08:51","pubTimestamp":1764636680,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业12月02日在投资者关系平台上答复投资者关心的问题。会不会出现不利于公司股东的价格波动?会不会两个上市价格互相影响?企业价值锚定公司基本面与长期发展潜力，而市场的交易价格体现了市场内部买卖力量的对比变化。两地定价核心逻辑会相互影响，资金的跨市场流动将推动两地价格向市场当前认可的估值区间靠拢，从长期来看，可以期待市场价格能够全面、客观地反映企业价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200004415.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91287","300558","BK0060","BK0239"],"gpt_icon":0},{"id":"2588702526","title":"贝达药业：H股募集资金将用于在研管线研发及潜在收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2588702526","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588702526?lang=zh_cn&edition=full","pubTime":"2025-12-02 08:51","pubTimestamp":1764636679,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业12月02日在投资者关系平台上答复投资者关心的问题。本次发行H股所募集资金在扣除发行费用后全部用于公司发展，可能包括用于在研管线的研发活动提供支持、为开拓管线而进行的潜在的收购以及进一步开拓创新生态圈、营销网络建设及重点治疗领域市场拓展、营运资金及其他一般公司用途。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200004413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91287","300558","BK0060","BK0239"],"gpt_icon":0},{"id":"2588023627","title":"贝达药业：嵊州基地将承接上市药品生产需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2588023627","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588023627?lang=zh_cn&edition=full","pubTime":"2025-12-02 08:48","pubTimestamp":1764636499,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业12月02日在投资者关系平台上答复投资者关心的问题。投资者提问：欣闻贵公司的两个重大项目——嵊州基地和梦工厂二期项目在2025年已经完工并投入试生产，特向贵公司表示热烈祝贺！公司对生产产能已提前做好充分的规划，嵊州创新药产业化基地将逐步承接公司上市药品的生产需求，同时也储备了部分在研新药的生产能力，公司将根据经营的需要逐步释放项目的生产保障能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200004389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300558","BK0060","91287"],"gpt_icon":0},{"id":"2588470258","title":"贝达药业：恩沙替尼术后辅助治疗适应症上市许可申请已获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2588470258","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588470258?lang=zh_cn&edition=full","pubTime":"2025-12-02 08:48","pubTimestamp":1764636498,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业12月02日在投资者关系平台上答复投资者关心的问题。贵公司恩莎替尼术后NDA已经拖了3个多月，是否与此有关？恩沙替尼术后辅助治疗适应症上市许可申请已获得国家药品监督管理局受理，详见公司披露在巨潮咨询网上的《关于盐酸恩沙替尼胶囊术后辅助治疗适应症药品注册申请获得受理的公告》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200004388.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","91287","300558"],"gpt_icon":0},{"id":"2586201086","title":"贝达药业(300558.SZ)：盐酸恩沙替尼胶囊上市许可申请获得欧洲药品管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2586201086","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586201086?lang=zh_cn&edition=full","pubTime":"2025-11-28 15:52","pubTimestamp":1764316350,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝达药业 发布公告，今日，公司控股子公司Xcovery收到欧洲药品管理局通知，Xcovery递交的盐酸恩沙替尼胶囊“拟用于间变性淋巴瘤激酶阳性的局部晚期或转移性非小细胞肺癌成年患者的治疗”的上市许可申请已获得EMA受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","91287","BK0060","300558"],"gpt_icon":0},{"id":"2586728780","title":"贝达药业(300558.SZ)：盐酸恩沙替尼胶囊术后辅助治疗适应症药品注册申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2586728780","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586728780?lang=zh_cn&edition=full","pubTime":"2025-11-26 12:07","pubTimestamp":1764130038,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝达药业(300558.SZ)发布公告，公司收到国家药品监督管理局(以下简称“NMPA”)签发的《受理通知书》(受理号：CXHS2500142、CXHS2500143)，公司申报的盐酸恩沙替尼胶囊(商品名：贝美纳®，以下简称“恩沙替尼”)拟用于“间变性淋巴瘤激酶(ALK)阳性的IB期至IIIB期非小细胞肺癌(NSCLC)患者的术后辅助治疗，患者须既往接受过手术切除治疗，并由医生决定接受或不接受辅助化疗”的上市许可申请已获得NMPA受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373759.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300558","91287","BK0060"],"gpt_icon":0},{"id":"2583579204","title":"11月14日贝达药业现1笔折价19.77%的大宗交易 合计成交300.7万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583579204","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583579204?lang=zh_cn&edition=full","pubTime":"2025-11-14 17:25","pubTimestamp":1763112311,"startTime":"0","endTime":"0","summary":"证券之星消息，11月14日贝达药业发生大宗交易，交易数据如下：大宗交易成交价格43.58元，相对当日收盘价折价19.77%，成交6.9万股，成交金额300.7万元，买方营业部为广发证券股份有限公司广州黄埔大道证券营业部，卖方营业部为方正证券股份有限公司株洲攸县大巷路证券营业部。近三个月该股共发生8笔大宗交易，合计成交8405.0手，折价成交8笔。截至2025年11月14日收盘，贝达药业报收于54.32元，下跌0.29%，换手率1.32%，成交量5.55万手，成交额3.03亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400027721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","91287","BK0060","BK0239"],"gpt_icon":0},{"id":"2582387231","title":"贝达药业：截至2025年6月30日公司共有1,800余名员工","url":"https://stock-news.laohu8.com/highlight/detail?id=2582387231","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582387231?lang=zh_cn&edition=full","pubTime":"2025-11-11 09:15","pubTimestamp":1762823711,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业11月11日在投资者关系平台上答复投资者关心的问题。据公司回应，有销售人员约1100人，产品覆盖31个省市的2500余家医院。因为据同行业销售伏美替尼公司互动易信息，其拥有销售人员超过3000人，产品覆盖31个省市的5000家医院。截至2025年6月30日，公司共有1,800余名员工，研发团队近300人，商业化团队1,100余人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100005533.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","91287","300558","BK0060"],"gpt_icon":0},{"id":"2582387471","title":"贝达药业：与瑞普晨创合作推进1型糖尿病细胞治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2582387471","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582387471?lang=zh_cn&edition=full","pubTime":"2025-11-11 09:15","pubTimestamp":1762823710,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业11月11日在投资者关系平台上答复投资者关心的问题。公司与杭州瑞普晨创科技有限公司已签署《战略合作协议》并进行投资，双方在人多能干细胞向胰岛细胞诱导分化技术领域展开深入合作。目前，瑞普晨创自主研发的RGB-5088胰岛细胞注射液治疗1型糖尿病的临床研究已在推进当中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100005530.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","91287","BK0060","300558"],"gpt_icon":0},{"id":"2582387980","title":"贝达药业：四驾马车协同发展提升内在价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2582387980","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582387980?lang=zh_cn&edition=full","pubTime":"2025-11-11 09:12","pubTimestamp":1762823528,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业11月11日在投资者关系平台上答复投资者关心的问题。股价短期波动受市场多重因素影响，长期更多取决于企业自身价值。目前公司正在积极推进市场销售、新药研发、战略合作、创新生态圈“四驾马车”协同发展，聚焦主业着力提升公司内在价值，并加强与市场的沟通，通过加倍的努力为投资者带来可持续回报。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100005456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91287","BK0060","300558","BK0239"],"gpt_icon":0},{"id":"2581363350","title":"贝达药业：恩沙替尼术后辅助治疗达主要研究终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2581363350","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581363350?lang=zh_cn&edition=full","pubTime":"2025-11-06 11:51","pubTimestamp":1762401070,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)11月06日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，恩沙替尼的术后辅助适应症临床进展如何？什么时候可以申报上市？贝达药业回复：您好！恩沙替尼用于ALK阳性NSCLC术后辅助治疗的药物临床试验期中数据分析显示阳性结果，达到预设的主要研究终点，公司团队正加紧准备申报材料，尽快递交新增适应症的NDA申请。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600014992.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["91287","300558","BK0060","BK0239"],"gpt_icon":0},{"id":"2581737039","title":"贝达药业：BPI-572270是一款分子胶抑制剂，目前该项目正推进提交临床研究申请（IND）准备工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2581737039","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581737039?lang=zh_cn&edition=full","pubTime":"2025-11-06 11:41","pubTimestamp":1762400460,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：公司的分子胶和降解剂项目何时可以申报临床？贝达药业（300558.SZ）11月6日在投资者互动平台表示，BPI-572270是一款分子胶抑制剂，目前该项目正在推进提交临床研究申请（IND）的准备工作。CFT8919片是一种具有口服生物利用度的变构 BiDAC 降解剂，CFT8919项目目前在临床Ⅰ期研究中。（文章来源：每日经济新闻）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-06/doc-infwmrcc5817416.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-06/doc-infwmrcc5817416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0060","BK0239","BPI","300558","91287"],"gpt_icon":0},{"id":"2581084496","title":"贝达药业：MCLA-129、CFT8919项目正在临床研究中","url":"https://stock-news.laohu8.com/highlight/detail?id=2581084496","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581084496?lang=zh_cn&edition=full","pubTime":"2025-11-06 08:42","pubTimestamp":1762389733,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业11月06日在投资者关系平台上答复投资者关心的问题。对于肺癌治疗领域的持续用药品种，公司目前有MCLA-129、CFT8919项目正在临床研究中，公司会集中资源，聚焦研究，尽早取得新药项目的开发进展。同时，鉴于创新药开发的不确定性，公司也有成熟的评估机制动态评价项目价值，及时调整，做好公司管线妥善布局和研发资源高效利用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600005715.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060","91287"],"gpt_icon":0},{"id":"2581084440","title":"贝达药业：2025年1-9月实现营业收入27.17亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2581084440","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581084440?lang=zh_cn&edition=full","pubTime":"2025-11-06 08:42","pubTimestamp":1762389733,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业11月06日在投资者关系平台上答复投资者关心的问题。目前，公司上市产品已达八款，得益于药品销量的增长以及新产品的逐步放量，2025年1-9月实现营业收入27.17亿元，同比增长15.90%；公司息税折旧摊销前利润达到8.6亿元，同比增长20.15%，体现了公司良好的发展势头。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600005716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","91287"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765347035658,"stockEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":-0.1106},{"period":"3month","weight":-0.3294},{"period":"6month","weight":-0.251},{"period":"1year","weight":-0.1327},{"period":"ytd","weight":-0.1028}],"compareEarnings":[{"period":"1week","weight":0.003},{"period":"1month","weight":-0.022},{"period":"3month","weight":0.0255},{"period":"6month","weight":0.149},{"period":"1year","weight":0.149},{"period":"ytd","weight":0.1664}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"贝达药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"34761人(较上一季度增加17.69%)","perCapita":"12065股","listingDate":"2016-11-07","address":"浙江省杭州市临平区经济技术开发区兴中路355号","registeredCapital":"42073万元","survey":" 贝达药业股份有限公司的主营业务是创新药物的生产与销售。公司的主要产品是凯美纳、贝美纳、贝安汀、赛美纳、伏美纳、康美纳、安瑞泽、奥福民。","listedPrice":17.57},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"贝达药业,300558,贝达药业股票,贝达药业股票老虎,贝达药业股票老虎国际,贝达药业行情,贝达药业股票行情,贝达药业股价,贝达药业股市,贝达药业股票价格,贝达药业股票交易,贝达药业股票购买,贝达药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}